SCHEMBL5246128

SCHEMBL5246128

CCc1ccc2oc(N3CCN4CCC3CC4)nc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 5/20 1.00
KCNH2 Q12809 4/20 1.00
CHRNA7 P36544 4/20 0.73
CHRM4 P08173 1/20 0.73
CHRM5 P08912 1/20 0.73
CHRM1 P11229 1/20 0.73
CHRM3 P20309 1/20 0.73
CHRNB4 P30926 1/20 0.73
CHRNA3 P32297 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459339 0.84 HTR3A (1.00) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5307779 0.83 HTR3A (0.71) HTR3AKCNH2CHRNA7CHRM4CHRM5
Hydrochloric Acid SCHEMBL15663033 0.83 HTR3A (0.97) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL21851713 0.82 HTR3A (0.72) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5249020 0.79 HTR3A (0.65) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5909677 0.78 HTR3A (0.73) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5246684 0.78 HTR3A (0.64) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5532880 0.78 KCNH2 (0.73) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5247514 0.77 HTR3A (0.85) HTR3AKCNH2CHRNA7CHRM4CHRM5
SCHEMBL5249309 0.77 KCNH2 (0.72) HTR3AKCNH2CHRNA7CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814888-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS Pfizer Products Incorporated (US) 2007-08-08 EP claimed
US-20060173179-A1 Azabenzoxazoles for the treatment of CNS disorders PFIZER INC 2006-08-03 US claimed
WO-2006051394-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS PFIZER PRODUCTS INC. (US) 2006-05-18 WO claimed
EP-1831683-A1 METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR Pfizer Products Inc. (US) 2007-09-12 EP disclosed
EP-1814887-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS Pfizer Products Incorporated (US) 2007-08-08 EP disclosed
EP-1814888-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS Pfizer Products Incorporated (US) 2007-08-08 EP disclosed
US-20060173179-A1 Azabenzoxazoles for the treatment of CNS disorders PFIZER INC 2006-08-03 US disclosed
US-20060166974-A1 Azabenzoxazoles for the treatment of CNS disorders PFIZER INC. 2006-07-27 US disclosed
WO-2006067611-A1 METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR PFIZER PRODUCTS INC. (US) 2006-06-29 WO disclosed
WO-2006051407-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS PFIZER PRODUCTS INC. (US) 2006-05-18 WO disclosed
WO-2006051394-A1 AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS PFIZER PRODUCTS INC. (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166974-A1 Azabenzoxazoles for the treatment of CNS disorders CHRNA7, CHRNA5, CHRNA10 HTR3A 316/4885KCNH2 2357/4885CHRNA7 1/4885
US-20060173179-A1 Azabenzoxazoles for the treatment of CNS disorders CHRNA7, CHRNA5, CHRNA10 HTR3A 285/4885KCNH2 2095/4885CHRNA7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.